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An automated hepatitis C virus (HCV) antigen (Ag) assay was evaluated with clinical samples. Determina-
tion of HCV Ag and RNA levels in 282 subjects using Abbott HCV Ag and Roche Cobas TaqMan assays revealed
that these two tests were highly correlated (r  0.9464). Thus, the HCV Ag assay could be an alternative test
to quantitative reverse transcription-PCR.
Hepatitis C virus (HCV) infection usually causes a progres-
sive disease that can result in chronic hepatitis, liver cirrhosis,
and hepatocellular carcinoma (12). Diagnosis and monitoring
of HCV infection are commonly based on anti-HCV assays,
recombinant immunoblotting, and HCV RNA viral load in
current clinical practices (13). However, anti-HCV assays have
limitations, including a lack of detection sensitivity in the early
window periods of 45 to 68 days after infection (5), although
second- and third-generation anti-HCV assays have improved.
Real-time quantitative reverse transcription-PCR (qRT-PCR)
analyses for measuring viral loads also have some drawbacks.
These techniques are not completely free from contamination
and false-positive results. Furthermore, some PCR assays re-
quire technical skills and may also be labor intensive and ex-
pensive.
HCV core antigen (Ag) tests have been introduced to sup-
plement anti-HCV tests or HCV qRT-PCR analyses over the
last decade (1, 16), and these quantitative HCV Ag assays
could be used for the monitoring of antiviral therapy as well as
for diagnosis of HCV infection (3, 6). Furthermore, the HCV
Ag assay could also be useful in monitoring immunocompro-
mised patients and those undergoing hemodialysis (10). How-
ever, most of the past studies detecting HCV Ag utilized en-
zyme-linked immunosorbent assays (ELISAs) or enzyme
immunoassays (EIAs) (4, 7, 14, 18), which may need consid-
erable time and skills. Recently, a fully automated chemilumi-
nescent immunoassay (CLIA) with higher sensitivity and
throughput was developed to overcome shortcomings of the
conventional core Ag assays (11). Thus, we evaluated the newly
introduced HCV Ag assay and compared it with a quantitative
RNA assay to verify the utility of this automated Ag assay as an
alternative to HCV RNA qRT-PCR.
A total of 282 serum samples from the 268 patients who
visited a university hospital in Korea with suspected HCV
infection were collected from January to April 2009. HCV Ag
and qRT-PCR assays were performed for all 282 samples,
while anti-HCV antibodies and liver enzymes were measured
in 279 and 250 subjects, respectively. HCV genotyping was also
performed in 127 specimens. Serum HCV Ag was determined
by an Abbott Architect i2000SR analyzer (Abbott Laborato-
ries, Abbott Park, IL) with an HCV Ag assay kit (Abbott Japan
Co., Ltd., Tokyo, Japan). The Architect HCV Ag assay is a
two-step chemiluminescent microparticle immunoassay for the
quantitation of HCV core Ag. The sample volume required is
about 110 l, and the total assay time is 36 min. The cutoff
value is 3.0 fmol/liter; thus, HCV Ag levels below 3.0 fmol/liter
were considered nonreactive. HCV RNA viral load was deter-
mined by Cobas AmpliPrep/Cobas TaqMan HCV assay
(CAM/CTM) (Roche Molecular Systems, Inc., Pleasanton,
CA). The lower detection limit of CAM/CTM is 15 IU/ml.
Anti-HCV was tested using a Cobas e411 analyzer with Elecsys
Anti-HCV assay kit (Roche Diagnostics, Mannheim, Ger-
many). HCV genotyping was carried out using linear array
HCV genotyping (Roche Molecular Systems).
Statistical analysis was performed using SPSS 15.0 for Win-
dows (SPSS Inc., Chicago, IL). The correlation coefficients
between serum levels of HCV Ag and RNA were calculated by
Spearman’s rank test, and a comparison between the groups
was carried out using the Mann-Whitney U test. A P value of
0.05 was considered statistically significant.
Among the 282 specimens tested, all 108 cases in which
HCV RNA was not detected were nonreactive for HCV Ag. Of
the 161 cases in which HCV RNA levels exceeded 15 IU/ml,
157 (97.5%) were reactive for HCV Ag (Table 1). HCV RNA
levels of the 4 RNA-positive and HCV Ag-nonreactive speci-
mens were 73, 82, 261, and 814 IU/ml. Another group of 13
cases with HCV RNA levels below 15 IU/ml were all nonre-
active for HCV Ag. The qualitative results determined by
HCV Ag and HCV RNA assays showed an agreement of
94.0%. Sensitivity, specificity, and positive and negative pre-
dictive values (PPV and NPV) of the HCV Ag test for pre-
dicting HCV RNA detection were 90.2%, 100%, 100%, and
86.4%, respectively.
Figure 1 illustrates individual HCV Ag and RNA concen-
trations and it shows a good correlation between them (r 
0.9464; 95% confidence interval [CI], 0.9327 to 0.9574; P 
0.0001). Correlation coefficients were also calculated in 127
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genotyped cases, and those of groups with genotypes 1, 2, and
3 were 0.9521 (n  76; 95% CI, 0.9253 to 0.9695; P  0.0001),
0.9513 (n  45; 95% CI, 0.9126 to 0.9731; P  0.0001), and
0.9429 (n  6; 95% CI, 0.5591 to 0.9939; P  0.0048), respec-
tively.
In the HCV RNA detected cases, the group classifications
were made arbitrarily by HCV RNA levels of 105, 105 to 107,
and 107 IU/ml (groups A, B, and C, respectively). Median
HCV Ag levels of those groups were 11.1, 3,629.8, and 15,189.8
fmol/liter, respectively, and there were significant differences
between them (P  0.0001) (Fig. 2A). However, the distribu-
tions of HCV Ag levels in groups B and C were considerably
overlapped; therefore, the RNA-to-Ag ratio in each group was
calculated. Median values of the RNA-to-Ag ratio in the
groups A, B, and C were 300.5, 645.7, and 1,180.5 kIU/fmol
(RNA/Ag), respectively, and significant differences between
the ratios were also noted (P  0.0013 for group A versus B,
and P  0.0001 for group B versus C) (Fig. 2B). Based on the
linear regression analysis of cases with HCV RNA exceeding
15 IU/ml (n  161), the following equation was established
(r2  0.8679): HCV Ag (log10 fmol/liter)  0.7881  HCV
RNA (log10 IU/ml)  1.4955.
Among 279 samples in which anti-HCV and HCV Ag were
qualitatively determined, 48 of 125 (38.4%) HCV Ag-nonre-
active cases were positive for anti-HCV. Among these, HCV
RNA was not detected in 35 subjects, and HCV RNA levels of
9 cases were below 15 IU/ml (Table 1). The four HCV Ag-
nonreactive cases in the group which showed negative results
for anti-HCV as well as HCV RNA levels below 15 IU/ml were
from patients undergoing hemodialysis multiple times. All the
HCV Ag-reactive cases (n  154) were also positive for anti-
HCV (Table 1). The percent agreement between HCV Ag and
anti-HCV was 82.8%. Although HCV Ag was highly correlated
with HCV RNA, positive correlations of HCV Ag with anti-
HCV antibodies (r  0.5762; P  0.0001) and liver enzymes
(r  0.5683 for aspartate transaminase [AST]; r  0.5408 for
alanine transaminase [ALT]; P  0.0001) were also found.
In this study, HCV Ag concentrations were strongly corre-
lated with HCV RNA levels (r 0.9464). The newly developed
automated HCV Ag assay could be used as an alternative test
for HCV RNA assays, considering the correlation coefficient
between them. In the previous report, which utilized the same
Ag assay and a different RNA assay (Roche Cobas Amplicor
HCV monitor 2.0), the correlation coefficient was 0.74 (n 
197) (11). Another HCV Ag assay also showed a good corre-
lation (n 213; r 0.848) with the Amplicor HCV monitor 2.0
assay (18).
According to the manufacturer’s declaration, the lower de-
tection limit of the CAM/CTM is as low as 15 IU/ml, while that
of the Cobas Amplicor HCV monitor 2.0 is 500 IU/ml. In
addition, CLIA, which is used for the Architect HCV Ag assay,
is known to be more sensitive than ELISA or EIA. The ana-
lytical sensitivity of the Architect HCV Ag assay was shown to
be 3 fmol/liter (equivalent to 0.06 pg/ml of recombinant c11 Ag
or approximately 440 IU/ml HCV RNA) (11), while that of a
conventional HCV Ag assay by ELISA was 2.3 pg/ml; i.e.,
approximately 16,600 IU/ml RNA (2). Further evaluations
with more specimens would be helpful to calculate the corre-
lation coefficient between the Architect HCV Ag assay and the
CAM/CTM, since this is the first study that demonstrated the
correlation between them.
In addition, the HCV RNA-to-Ag ratio from our data was
not constant but increased as the RNA level was increased.
These data suggest that more HCV core Ag is released into the
blood as more viral replication occurs, but not as much as the
increment of viral load. This is plausible, since viral core Ag is
not a direct marker of replication. Bouvier-Alias et al. (2)
demonstrated that the variation of the RNA/Ag ratio resulted
from the interindividual difference and suggested that 1 pg/ml
Ag was equivalent to about 8,000 IU/ml RNA (5,000 to 12,000
IU/ml in the majority). However, based on the equation gen-
erated from our result, 1 pg/ml Ag corresponds roughly to
17,000 IU/ml RNA. This disagreement might be due to the
TABLE 1. Summary of HCV Ag, HCV RNA, and anti-HCV test results
HCV Ag
HCV RNA (no. of anti-HCV positive/total)
Not detected 15 IU/ml 15 IU/ml Total
Nonreactive (3 fmol/liter) 108 (35/108) 13 (9/13a) 4 (4/4) 125 (48/125)
Reactive (3 fmol/liter) 0 (0/0) 0 (0/0) 157 (154/154b) 157 (154/154)
Total 108 (35/108) 13 (9/13) 161 (158/158) 282 (202/279c)
a The four anti-HCV-negative and HCV Ag-nonreactive cases were from patients undergoing hemodialysis multiple times.
b Anti-HCV was positive in all 154 cases of which HCV Ag was reactive and the HCV RNA level was over 15 IU/ml.
c Of the total 282 specimens tested for HCV RNA and Ag, 279 samples were assayed for anti-HCV.
FIG. 1. Correlation between HCV Ag and HCV RNA concentra-
tions. The levels of HCV Ag were highly correlated with those of HCV
RNA by the Spearman’s rank correlation test (r 0.9464; P 0.0001).
x and y axes are log scaled. ND, not detected.
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difference between the assays adopted and would hinder the
exact conversion between RNA and Ag concentrations. A
more precise RNA-to-Ag ratio and the exact nature of its
variation need to be assessed in further studies.
As expected, qRT-PCR was more sensitive than the HCV
Ag assay. Of the 161 samples with HCV RNA exceeding 15
IU/ml, 157 cases were reactive for the HCV Ag assay, giving a
detection rate of 97.5%. However, HCV RNA levels were low
(15 IU/ml) in 13 of 17 (76.5%) cases in which HCV RNA was
detected but HCV Ag was nonreactive. HCV RNA levels of
the remaining 4 HCV RNA-positive, HCV Ag-nonreactive
samples were below the detection limit of the Architect HCV
Ag assay (approximately 440 IU/ml RNA) except one with 814
IU/ml. These results suggest that the Architect HCV Ag assay
is less sensitive than CAM/CTM because of its detection limit.
However, the HCV Ag assay demonstrated 100% specificity
and PPV from our data, although overall sensitivity for detect-
ing HCV RNA-positive cases was 90.2% (157/174 subjects). In
the previous study of HCV Ag performed in patients that have
undergone liver transplantations, a similar detection rate of
92% (378/410 cases) was reported (9). Improving the lower
detection limit would enhance the analytical power of the
HCV Ag assay.
We have evaluated the correlation between HCV Ag and
HCV RNA with clinical specimens. Since there were no HCV
Ag-reactive and anti-HCV-negative cases, we were not able to
identify whether the early HCV infection without antibodies
could be detected using the HCV Ag assay. However, Leary et
al. (8) demonstrated that the HCV Ag was detected prior to
the appearance of anti-HCV in the patients’ sera and this
phenomenon may have resulted in a reduction of the window
period by 23 days or even longer. HCV Ag was also detected
from more than 97% of HCV RNA-positive and antibody-
negative samples in the same study.
There were 48 HCV Ag-nonreactive and anti-HCV-positive
cases in this study. Among these cases, HCV RNA was not
detected or was below 15 IU/ml in 44 (91.7%) cases, which may
indicate stable infections (chronic infections without active
viral replication). In addition, HCV RNA was not detected or
was below 15 IU/ml in 121 (96.8%) of the 125 HCV Ag-
nonreactive cases, irrespective of anti-HCV test results. There-
fore, determination of the HCV Ag level would facilitate the
distinction between active viral replication and stable infection
and might be used to monitor the responses to antiviral ther-
apies.
This study focused mainly on the evaluation of the correla-
tion between HCV Ag and HCV RNA. Thus, we could not
assess the effect of antiviral therapies on levels of HCV Ag and
RNA. We also generated limited data regarding the effect of
HCV genotypes on the correlation. Our results suggest that the
FIG. 2. HCV Ag levels and RNA-to-Ag ratio according grouped by HCV RNA levels. (A) Median HCV Ag levels were 11, 3,630, and 15,190
fmol/liter for the groups of RNA levels 105, 105 to 107, and 107 IU/ml (groups A, B, and C), respectively. HCV Ag levels showed significant
differences between those groups (P 0.0001). (B) The RNA-to-Ag ratios of those groups were also significantly different from each other (median
of 301, 646, and 1,181 kIU/fmol for groups A, B, and C, respectively) (P  0.0013 for group A versus B, and P  0.0001 for group B versus C).
The upper and lower ends of boxes and box inner lines correspond to the upper and lower quartiles and median values, respectively. Whiskers
denote minimum and maximum values, and circles indicate individual values.
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HCV genotype does not influence the correlation. However, a
previous study reported that the correlation coefficients were
different from each other according to the genotype (17). In
another study, HCV Ag and RNA levels were better correlated
before therapy than after therapy (15). Further research on
these subjects with the automated HCV Ag assay might be
needed to clarify the relationship between HCV Ag and RNA,
depending on the genotypes and therapies.
In conclusion, the automated HCV Ag assay showed results
comparable to those of the HCV RNA viral load assay, and it
has the advantages of easy testing and rapid reporting. This
assay would be useful to monitor HCV infection and to dis-
criminate active viral replication states from stable infections
and could be an alternative to the quantitation of HCV RNA
levels using qRT-PCR.
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